Myriad Genetics, Inc.
NASDAQ:MYGNMedical - Diagnostics & Research
+$0.14 today
- Market cap
- $530.45M
- Beta
- 1.64
- P/E (TTM)
- -1.1
- EPS (TTM)
- -$4.27
Volume 1.26M
Average 1.81M
MYGN Accounts Receivables
Cash effect of the change in amounts owed by customers; growing receivables consume cash.
Myriad Genetics, Inc.NASDAQ: MYGN
Accounts Receivables · Q1 FY2026 · quarter ended Mar 2026
Accounts receivables turns negative
Q1 FY2026 accounts receivables was -$8.7M, compared with $800K a year earlier. Trailing-twelve-month accounts receivables was -$3.3M. Over 3 fiscal years it compounded at -7.0% a year.
Context
- Accounts receivables amounted to 0.8% of revenue in FY2025, down 0.3 pp from a year earlier.
- Accounts receivables increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly accounts receivables holds near -$8.7M or moves back toward the trailing-twelve-month quarterly average of -$825K.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Receivables history
USD · from the cash flow
- Latest · FY2025
- 6.2M USD
- Year-over-year change
- +171.3%
| Period | Period end | Accounts Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 6.2M | +171.3% |
| FY2024 | 2024-12-31 | (8.7M) | -328.9% |
| FY2023 | 2023-12-31 | 3.8M | -50.6% |
| FY2022 | 2022-12-31 | 7.7M | +187.5% |
| FY2021 | 2021-12-31 | (8.8M) | — |
Accounts Receivables vs competitors
How MYGN compares with its peers on the latest reported figures
- MYGN's LTM Mar 2026 accounts receivables of $3.3M is the 8th largest of the 10 companies compared; the peer median is $7.31M.
- Its year-over-year change of -17.5% is the 5th highest of 9, against a peer median of +43.7%.
- Accounts receivables amounts to 0.4% of revenue for MYGN, versus a peer median of 3.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $109.63M | -510.4% | — | 4.0% | |
| LTM Sep 2026 | $70.6M | +155.1% | — | 5.5% | |
BLLNBillionToOne, Inc. | LTM Jun 2026 | $44.46M | — | — | 11.2% |
| LTM Jun 2026 | $22.74M | +538.2% | -6.6% | 3.0% | |
| LTM Jun 2026 | $7.31M | -67.7% | — | 0.3% | |
| LTM Jun 2026 | $6.15M | +922.3% | -46.0% | 1.1% | |
IMDXInsight Molecular Diagnostics Inc. | LTM Mar 2026 | $3.38M | +200.1% | — | 173.6% |
| LTM Mar 2026 | $3.3M | -17.5% | -7.0% | 0.4% | |
| LTM Mar 2026 | $2.3M | -89.7% | — | 0.7% | |
| LTM Mar 2026 | $2.05M | -650.8% | — | 3.2% | |
| Peer median (excluding MYGN) | $7.31M | +43.7% | -26.3% | 3.2% | |
Competitors are the stored peer set for MYGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (27.2M) | (112M) | (263.3M) | (127.3M) | (365.9M) |
| Depreciation & Amortization | 62.8M | 52.7M | 61.9M | 61.2M | 53.7M |
| Deferred Income Tax | (34.7M) | (31.9M) | (600K) | (300K) | (32.4M) |
| Stock-Based Compensation | 36.3M | 38.1M | 40.7M | 49.8M | 35.2M |
| Change in Working Capital | 120.8M | (83.5M) | 27M | (54.4M) | (19.3M) |
| Accounts Receivables | (8.8M) | 7.7M | 3.8M | (8.7M) | 6.2M |
| Inventory | 1.6M | (2.9M) | (1.8M) | (6.2M) | (3.2M) |
| Accounts Payables | 9.2M | (3.5M) | (3.7M) | 4.7M | (1.4M) |
| Other Working Capital | 118.8M | (84.8M) | 28.7M | (44.2M) | (20.9M) |
| Other Non-Cash Items | (139.4M) | 30.3M | 23.4M | 62.3M | 21.1M |
| Operating Cash Flow | 18.6M | (106.3M) | (110.9M) | (8.7M) | 1.8M |
| Capital Expenditures | (18M) | (45.3M) | (73.3M) | (29.7M) | (15.6M) |
| Acquisitions (Net) | 379.1M | (57.2M) | 0 | 8.8M | 0 |
| Purchases of Investments | (147.8M) | (103.2M) | 0 | 0 | 0 |
| Sales of Investments | 61.1M | 128.2M | 105.2M | 9M | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 274.4M | (77.5M) | 31.9M | (11.9M) | (27.4M) |
| Debt Repayment | (226.4M) | — | 39.8M | 100K | 75.9M |
| Common Stock Issued | 0 | 0 | 117.6M | 0 | 3.3M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 75.8M | (8M) | (4.5M) | (7.5M) | (15M) |
| Financing Cash Flow | (150.6M) | (8M) | 152.9M | (7.4M) | 64.2M |
| Effect of Forex Changes | (600K) | (600K) | 600K | (1M) | 800K |
| Net Change in Cash | 141.8M | (192.4M) | 74.5M | (29M) | 39.4M |
| Free Cash Flow | 600K | (151.6M) | (184.2M) | (38.4M) | (13.8M) |
Myriad Genetics, Inc.
NASDAQ:MYGN
Intrinsic Alpha fair value
Locked
Current Price
$5.53
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.